Researchers studied whether a combination of two drugs, amivantamab and lazertinib, works better than the standard single drug, osimertinib, for treating a specific type of advanced lung cancer. The study involved 629 Asian patients who had never received treatment for their EGFR-mutant non-small cell lung cancer. They were randomly assigned to receive either the combination therapy, osimertinib alone, or lazertinib alone, and were followed for a median of about 39 months.
The main finding was that patients who received the amivantamab-lazertinib combination lived longer, on average, than those who received osimertinib. The data showed a 26% lower risk of death for the combination group. After three years, 61% of patients on the combination were alive, compared to 53% on osimertinib. The safety of the combination was reported to be consistent with what was seen in the larger trial population, though specific side effect details were not provided in this analysis.
It is important to be careful with these results for a few reasons. This was a subset analysis, meaning it looked at a specific group of patients from a larger trial. The statistical significance was described as 'nominal,' which suggests the finding needs further confirmation. Also, the median survival time for the combination group was 'not reached,' and any projection of how much longer it might be is based on a statistical assumption, not a direct measurement.
For readers, this research suggests the amivantamab-lazertinib combination is a promising first-line treatment option for this specific patient group. However, it is not yet a definitive new standard. Patients should discuss all available treatment options, including potential benefits and side effects, with their oncologist to make the best personal decision.